A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
第2/3相
完了
NCT03019185
| 対象疾患 | Alport Syndrome |
|---|
| 相 | 第2/3相 |
|---|
| スポンサー | Biogen |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 187 名 |
|---|
| 介入（薬剤） | Placebo Oral Capsule, Bardoxolone Methyl |
|---|
| 開始日 | 2017年3月2日 |
|---|
| 完了日 | 2020年10月6日 |
|---|
| 結果公開日 | 2023年10月11日 |
|---|
概要
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2)
Baseline through 12 weeks after participant receives the first dose in the Phase 2 study · mL/min/1.73 m^2
| Phase 2 Bardoxolone Methyl | 13.37 ± 1.4111 mL/min/1.73 m^2 |
|---|
| p-value | <0.0001 |
|---|
| LS Mean change from baseline | 13.37 (95% CI 10.48–16.27) |
|---|
Change From Baseline in eGFR After 48 Weeks of Treatment (Phase 3)
Baseline through 48 weeks after participant receives the first dose in the Phase 3 study · mL/min/1.73 m^2
| Phase 3 Placebo | -4.77 ± 1.248 mL/min/1.73 m^2 |
|---|
| Phase 3 Bardoxolone Methyl | 4.71 ± 1.307 mL/min/1.73 m^2 |
|---|
| p-value | <0.0001 |
|---|
| LS Mean difference (Net) | 9.49 (95% CI 5.38–13.60) |
|---|
Change From Baseline in eGFR After 100 Weeks of Treatment (Phase 3)
Baseline through 100 weeks after participant receives the first dose in the Phase 3 study · mL/min/1.73 m^2
| Phase 3 Placebo | -8.45 ± 1.478 mL/min/1.73 m^2 |
|---|
| Phase 3 Bardoxolone Methyl | -0.81 ± 1.556 mL/min/1.73 m^2 |
|---|
| p-value | 0.0005 |
|---|
| LS Mean difference (Net) | 7.65 (95% CI 3.41–11.89) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。